Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Taiki YamaguchiDepartment of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji 192-0392, Tokyo, Japan.ORCID 0009-0003-4453-061X
Yoko Endo-TakahashiDepartment of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji 192-0392, Tokyo, Japan.ORCID 0000-0002-6881-6044
Takumi AmanoDepartment of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji 192-0392, Tokyo, Japan.
Arina IharaDepartment of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji 192-0392, Tokyo, Japan.
Tetsushi SakumaLaboratory of Genome Editing Breeding, Graduate School of Agriculture, Kyoto University, 448-5 Kajiicho, Kamigyo-ku, Kyoto-shi 602-0841, Kyoto, Japan.ORCID 0000-0003-0396-1563
Takuya FukazawaDepartment of General Surgery, Kawasaki Medical School, 2-6-1 Nalasange, Kita-ku, Okayama 700-8505, Okayama, Japan.
Yoichi NegishiDepartment of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji 192-0392, Tokyo, Japan.
Funding
JST SPRING JPMJSP2134Nagai Memorial Research Scholarship from the Pharmaceutical Society of Japan N-232602Naito Foundation None
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
cancer gene therapyCRISPR interferencegene deliverynanobubblesSOX2squamous cell carcinomaultrasoundΔNp63
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Therapeutic pCRISPRi Delivery to Lung Squamous Cell Carcinoma by Combining Nanobubbles and Ultrasound. · full record | OpenQuestion